ASCO Annual Meeting | Conference

Dr. Velcheti on the Safety of Nemvaleukin in Solid Tumors

June 7th 2022

Vamsidhar Velcheti, MD, discusses the safety of nemvaleukin alfa in patients with advanced solid tumors in the phase 1/2 ARTISTRY-1 trial.

Larotrectinib Elicits OS Benefit Vs SOC in TRK Fusion–Positive Tumors

June 7th 2022

Larotrectinib demonstrated longer overall survival compared with standard-of-care therapy in patients with TRK fusion–positive cancer.

Cobimetinib/Vemurafenib Combo Showcases Antitumor Activity in BRAF-Mutated Solid Tumors

June 7th 2022

A combination comprised of cobimetinib and vemurafenib demonstrated evidence of antitumor activity in patents with advanced solid tumors harboring BRAF V600E and other mutations who are not otherwise eligible to receive other FDA-approved therapies.

Seribantumab Elicits Deep, Durable Responses in Solid Tumors Harboring NRG1 Fusions

June 7th 2022

Seribantumab was found to produce encouraging overall response rates with acceptable tolerability when used as a monotherapy in patients with solid tumors harboring NRG1 fusions.

Adagrasib Delivers Durable CNS-Specific Activity in KRAS G12C+ NSCLC

June 7th 2022

Adagrasib led to an intracranial objective response rate of 32% and a median intracranial duration of response that was not reached in patients with KRAS G12C–mutant non–small cell lung cancer and active, untreated CNS metastases, according to findings from the KRYSTAL-1 trial.

Afatinib Efficacy and Safety to Be Investigated in Metastatic Solid Tumors With NRG1 Fusions

June 7th 2022

Afatinib may prove effective and tolerable in patients with advanced or metastatic solid tumors with NRG1 gene fusions, according to the rationale for a prospective real-world outcomes study that was presented as a trial in progress at the 2022 ASCO Annual Meeting.

Selinexor Demonstrates PFS Benefit in Advanced Endometrial Cancer, Including p53 Wild-Type Tumors

June 7th 2022

Selinexor generated a longer median progression-free survival compared with placebo in patients with advanced or recurrent endometrial cancer, including those with p53 wild-type tumors.

PDS0101 Shows Synergistic Activity With Pembrolizumab in HPV16+ Head and Neck Squamous Cell Carcinoma

June 7th 2022

The combination of PDS0101 and pembrolizumab led to encouraging responses and favorable safety with no grade 3 or greater treatment-related adverse effects in patients with checkpoint inhibitor–naïve HPV16-positive recurrent or metastatic head and neck squamous cell carcinoma, according to findings from a prespecified interim analysis of the phase 2 VERSATILE-002 study.

Rivoceranib Elicits Promising Responses in Adenoid Cystic Carcinoma

June 7th 2022

The oral VEGFR2 TKI rivoceranib demonstrated an objective response rate by investigator assessed RECIST 1.1 criteria of 15.1% and a disease control rate of 64.4% for patients with recurrent or metastatic adenoid cystic carcinoma.

Zanubrutinib Plus Obinutuzumab Elicits Improved Response Rates in Relapsed/Refractory Follicular Lymphoma

June 7th 2022

The addition of zanubrutinib to obinutuzumab achieved an improved overall response rate, overall survival, and progression-free survival, compared with obinutuzumab alone, in patients with relapsed/refractory follicular lymphoma.

Dr. Botta on the Evaluation of CT041 in Gastric and Pancreatic Cancer

June 7th 2022

Gregory Botta, MD, PhD, discusses the evaluation of CT041 in patients with advanced gastric and pancreatic cancers in a phase 1b trial.

Dr. Rao on the Rationale of the CASPAR Trial in mCRPC

June 7th 2022

Arpit Rao, MD, discusses the rationale and importance of the phase 3 CASPAR trial in castration-resistant prostate cancer.

Pembrolizumab Produces Prolonged Survival in NSCLC With PD-L1 TPS ≥ 90%

June 7th 2022

Treatment with frontline pembrolizumab demonstrated meaningful improvements in long-term survival in patients with EGFR- or ALK- wild-type non–small cell lung cancer and a tumor proportion score of at least 90% vs those with a tumor proportion score between 50% and 89%, according to 3-year findings from a correlative analysis.

Larotrectinib Delivers Durable Improvement in HRQoL in TRK Fusion Cancers

June 7th 2022

Treatment with larotrectinib led to early onset and clinically meaningful improvements in health-related quality of life that were sustained for more than 12 months in most adult and pediatric patients with TRK fusion lung cancer, according to results from an expanded dataset.

Panitumumab Plus Intensified Chemotherapy Fails to Improve Efficacy in mCRC

June 7th 2022

The EGFR inhibitor panitumumab plus a stronger chemotherapy regimen did not demonstrate a significant response benefit over an active chemotherapy comparator plus panitumumab in patients with metastatic colorectal cancer with unmutated RAS and BRAF.

Darolutamide Lowers Risk of Metastatic Progression in Nonmetastatic CRPC

June 7th 2022

Darolutamide significantly reduced the risk of metastatic progression and improved overall survival, compared with placebo, in patients with nonmetastatic castration-resistant prostate cancer.

Pembrolizumab/Chemoradiation Maintains Efficacy in Previously Untreated Stage III NSCLC

June 7th 2022

Pembrolizumab plus concurrent chemoradiation, followed by single-agent pembrolizumab, maintained survival benefits in patients with previously untreated, locally advanced stage III non–small cell lung cancer.

Ribociclib Dose Reductions Do Not Affect Survival Outcomes in HR+/HER2- Advanced Breast Cancer

June 7th 2022

Overall survival outcomes for patients with hormone receptor–positive, HER2-negative advanced breast cancer who had dose modifications of ribociclib in the phase 3 MONALEESA-2 trial were comparable to those seen among patients who received the standard dose.

Sugemalimab and Chemotherapy Displays Significant OS Improvement in NSCLC

June 7th 2022

Sugemalimab plus chemotherapy improved overall survival (OS) vs placebo plus chemotherapy in patients with newly diagnosed metastatic non–small cell lung cancer, irrespective of PD-L1 expression or tumor histology.

Radiotherapy Unnecessary for Some Luminal A Breast Cancers

June 7th 2022

Radiotherapy can safely be omitted from treatment plans following breast conserving surgery without jeopardizing recurrence rates for patients aged 55 years and older who have low-grade, T1N0, luminal A breast cancer with a Ki67 expression of 13.25% or less, according to findings from the LUMINA study.